key: cord-1026677-nous57i0
authors: Shaaban, Mohamed R; Mayhoub, Abdelrahman S; Farag, Ahmad M
title: Recent advances in the therapeutic applications of pyrazolines
date: 2012-03-08
journal: Expert Opin Ther Pat
DOI: 10.1517/13543776.2012.667403
sha: d0aacbefff2b2cc1d18cb225ce77847ac3cb8899
doc_id: 1026677
cord_uid: nous57i0

Introduction: Pyrazolines are well-known and important nitrogen-containing five-membered ring heterocyclic compounds. Various methods have been worked out for their synthesis. Several pyrazoline derivatives have been found to possess diverse biological properties, which has stimulated research activity in this field. Areas covered: The present review sheds light on the recent therapeutic patent literature (2000 – 2011) describing the applications of pyrazolines and their derivatives on selected activities. Many of the therapeutic applications of pyrazoline derivatives have been discussed, either in the patent or in the general literature areas in this review. In addition to selected biological data, a wide range of pharmaceutical applications and pharmaceutical compositions are also summarized. Expert opinion: Pyrazoline derivatives have numerous prominent pharmacological effects, such as antimicrobial (antibacterial, antifungal, antiamoebic, antimycobacterial), anti-inflammatory, analgesic, antidepressant and anticancer. Further pharmacological effects include cannabinoid CB1 receptor antagonists, antiepileptic, antitrypanosomal, antiviral activity, MAO-inhibitory, antinociceptive activity, insecticidal, hypotensive, nitric oxide synthase inhibitor, antioxidant, steroidal and antidiabetic. Lastly, they also effect ACAT inhibition, urotensin II and somatostatin-5 receptors, TGF-β signal transduction inhibitors and neurocytotoxicity inhibitors activities. Many new pyrazoline derivatives have been synthesized and patented, but there are still new aspects to explore and work on.

Pyrazoline is a five-membered ring heterocycle having two adjacent nitrogen atoms within the ring. It has only one endocyclic double bond and is of basic in nature [1] . They are also known as dihydropyrazoles and their chemistry are closely related to pyrazoles. According to heterocyclic nomenclature, pyrazolines require that the nitrogen atoms to be numbered 1 and 2 in each structure. There are three well-known tautomeric structures for pyrazolines namely: 1-pyrazoline, 2-pyrazoline and 3-pyrazoline ( Figure 1 ). However, among these tautomeric structures, 2-pyrazoline is the most common.

Pyrazoline derivatives are electron-rich nitrogenous heterocycles, which play an important role in the diverse biological activities. Among its derivatives, 3-substituted pyrazolines seem to be the most attractive pyrazoline-type derivatives [2] . These heterocyclic compounds are widely occurring in nature in the form of alkaloids, vitamins, pigments and as constituents of plant and animal cell.

According to the X-ray analysis, pyrazoline ring has the structure of the five-membered dihydropyrazole ring and it has an envelope conformation [3] . The carbon atom at position-5 is deviated from the almost planar system of the other four atoms of the heterocyclic ring [4] . 2-Pyrazoline is insoluble in water but soluble in propylene glycol because of its lipophilic character [4] .

Diversely substituted pyrazolines and their derivatives embedded with variety of functional groups are important biologically active agents and a huge amount of research activities have been directed toward this class of compounds. Pyrazoline derivatives are typical ICT (intramolecular charge transfer) compounds [5] , and are known as a kind of fluorescent brightening agents because they have strong blue fluorescence in solution.

A classical synthesis of these compounds has been stimulated after the pioneering work of Fischer and Kn€ oevenagel in the late 19th century [6] . The reaction of a,b-unsaturated aldehydes and ketones with hydrazines became one of the most popular methods for the preparation of 2-pyrazolines [7, 8] . In this method, hydrazones are formed as intermediates, which can be subsequently cyclized to 2-pyrazolines in the presence of a suitable cyclizing reagent like acetic acid. An alternative route involves 1,3-dipolar cycloaddition of nitrileimines to carbon--carbon double bond of arylmethylene (arylidene derivatives of active methylene) compounds as well as acrylic and cinnamic acid derivatives [9] [10] [11] [12] [13] [14] [15] . The discovery of this class of compounds and considering their efficiency as drugs provides an outstanding case history of modern drug developments and also points out the unpredictability of pharmacological activity from structural modification of a prototype drug molecule. In general, pyrazoline derivatives display a broad spectrum of potential pharmacological activities and have wide medical applications.

2. Pyrazoline patents 2.1 Overview of patent activity In the last decade, a significant interest of research in heterocyclic chemistry has been directed to substituted 2-pyrazoline derivatives. Section 2.2 of this review focuses on the recent development on pyrazolines along with their biological properties in both regular literature and patents field. Recently, some important reviews have been published on pyrazoline compounds [16, 17] .

The present review casts light on the recent patents and literature that is directed toward the therapeutic applications of pyr- 2.2 Biological and therapeutic applications of pyrazolines 2.2.1 Cannabinoid CB1 receptor antagonists One of the most attractive subjects of intensive research on pyrazoline derivatives is cannabinoid receptor type 1 (CB1) antagonists due to their highly fruitful therapeutic features. CB1 receptor antagonists have good prospects in many therapeutic areas, such as smoking and alcohol addiction as well as cognitive impairment. Recently, new chemical entities (NCEs) with CB1 antagonistic properties, structurally related to rimonabant 1, have been disclosed by some academic research groups and several pharmaceutical companies as well. There are a considerable number of CB1 antagonists that are bioisosteres and derived from rimonabant (1) by replacement of the pyrazole moiety with other heterocyclic analogs like pyrazoline.

Recently, Marti et al. reported one-pot preparation of cinchonidine salt of (4S,5S)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid (2), which is useful as an intermediate in the preparation of cannabinoid CB1 neutral antagonists. The method is efficient to avoid isolation of intermediates and produces product in good yield and enantiomeric excess [18] .

. Pyrazoline heterocycle provides a structural core for building huge variety of biologically active compounds. . The pharmacological activity of pyrazolinebased compounds extends from central nervous system (CNS) applications to antimicrobials. . The most predominant pharmacological activity was observed for the class of 'antimicrobials'. . Cannabinoid receptor type 1 (CB1) pyrazoline modulators are very useful in treatment of obesity and schizophrenia. . Pyrazoline-containing cytotoxic compounds are not only useful in treatment of cancer, but also some of them act as cancer chemopreventive agents. . There are many reports centered on the antimycobaterium activity of pyrazoline-containing compounds, most of them have been assayed versus the vaccine-strain H37Rv.

This box summarizes key points contained in the article. Recent advances in the therapeutic applications of pyrazolines Also, synthesis of 3,4-diphenyl-4,5-dihydro-pyrazole-1-carboxylic acid hydrazide 3, which is used as CB1 modulators was achieved by Yoo et al. [19] . In CB1 receptor binding assay, pyrazoline 4 hydrochloride showed 97% affinity at 3 µM. So far, pyrazoline derivatives of the general structure 5 are claimed to be useful for the treatment of obesity and schizophrenia.

Preparation of the cannabinoid CB1 receptor ligand 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(cis-2,6-dimethylpiperidin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide (6a) have been reported by Soler et al. [20, 21] . Solid solutions and/or solid dispersions of 6a as racemate, or the (S)-enantiomer 6b were prepared efficiently in such patents. The same results have been achieved by Vela Hernandez for the preparation of (4S,5S)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(cis-2,6-dimethylpiperidin-1-yl)-4methyl-4,5-dihydro-1H-pyrazole-3-carboxamide (6b) as a cannabinoid CB1 neutral antagonist for treatment of food intake disorders [28, 29] .

In the same context, Mcelroy and Chorvat have achieved the preparation of substituted N-phenyl-5-phenyl-pyrazolin-3-yl amides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity, diabetes, dyslipidemias, cardiovascular disorders and/or hepatic disorders [22] .

3,4-Diarylpyrazoline derivatives 7 have been reported by Lange et al. as potent CB1 receptor antagonists. Compound 7 showed lower lipophilic characters. The dramatic change was the replacement of the arylsulfonyl group by a dialkylaminosulfonyl moiety. One of these compounds exhibited the highest CB1 receptor affinity as well as very potent CB1 antagonistic activity and a high CB1/CB2 subtype selectivity [23] .

Sulfonamide-containing pyrazoline derivatives of general structure 8 were prepared by Buschmann et al. [24] and were used as CB1 modulators. Compounds 9 have been prepared via a multistep synthesis starting from 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxylic acid. The pyrazoline 9 showed a high affinity to the CB1 receptor and IC 50 value of 14.1 nM.

A number of analogs of diaryl-2-pyrazoline-3-carboxamides 10 have been prepared by Srivastava et al. and were evaluated for appetite suppression and body weight reduction in animal models. Both of the bisulfate salt of (±)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3carboxylic acid morpholin-4-ylamide and (-)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3carboxylic acid morpholin-4-ylamide (11) showed significant body weight reduction in vivo. This was attributed to their CB1 antagonistic activity together with favorable pharmacokinetic profiles [25] .

Donohue et al. used the radio-labeled ligands of (-)-3-(4-chlorophenyl)-N-[(4-cyanophenyl)sulfonyl]-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamidine (12) for imaging of CB1 receptors in vivo with positron emission tomography (PET) for understanding their importance in neuropsychiatric disorders [26] . Also, some substituted pyrazoline derivatives 13 have been reported by Fisas-Escasany and Buschmann [27] and were evaluated for preventing weight gain. They reported a multistep synthesis of pyrazoline derivatives 14, starting from 4-chlorobenzaldehyde and ethyl pyruvate. Compounds 14 showed IC 50 value of 26 nM when tested in vitro for the rat CB1 receptor subtype.

In the same consequence, Buschmann et al. reported the preparation of 4-substituted pyrazoline derivatives 13 as cannabinoid receptor inhibitors for treating various diseases [34] .

Lange et al. [30] reported the reaction of (pentylhydrazono) acetic acid ethyl ester, with N-chlorosuccinimide (NCS) followed by in situ treatment with styrene, hydrolysis and amidation with 2-adamantanamine hydrochloride to afford the pyrazoline 16. The latter compound showed high affinity for cannabinoid receptors and agonistic activity on CB1 receptor, which is also useful for the treatment of multiple sclerosis and traumatic brain injury. 4,5-Dihydro-(1H)-pyrazole derivatives 17 and 18 have been prepared by Yildirim et al. [31] . Compounds containing the pyrazoline structure 17 are used as CB1 receptor modulators. Pyrazoline 18 exhibited pKi values of 8.1 and 8.4 for CB1 and CB2, respectively, in cannabinoid receptor affinity assays.

Indoline-substituted pyrazoline derivatives 20 and 21 have been reported as cannabinoid receptor modulators by Torrens-Jover et al. [32] . Compounds of the general structure 19 were tested for their cannabinoid activity in vivo.

In addition, azepane-or azocane-substituted pyrazoline derivatives 22 have been also prepared by Torrens-Jover et al. [33] .

Preparation of octahydropentalene-and cycloalkanesubstituted pyrazoline derivatives 23 and 24, respectively have been achieved by Torrens-Jover et al. [36, 37] . Some of the selected compounds of the general formula 25 were tested for their in vivo cannabinoid activity. Also, some prodrugs of pyrazoline compounds 25 have been prepared by Torrens-Jover et al. as CB1 receptor antagonists [38] [39] . The synthesized pyrazoline derivatives 26 have been investigated for cancer treatment or prophylaxis. Pyrazolines such as 27 and 28 could be successfully employed in treatment and/ or cancers prophylaxis of many types ranging from the brain, bone, mouth, esophagus, stomach, liver, bladder, pancreas, cervix, lung, breast, colon, rectum or prostate cancers.

Several novel thiazolone-based compounds containing 5-aryl-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl framework 29a have been reported by Havrylyuk et al. [40] . The synthesized compounds were evaluated in vitro for their cyctotoxic activity. Most of the tested compounds displayed promising anticancer activity versus variety of cancer types including leukemia, melanoma, lung, colon, ovarian, renal, prostate and breast cancer cell lines. Among these series, compound 29b showed the most efficient anticancer potency and was found to be active with selective influence on colon cancer cell lines, especially on HT-29 (log GI 50 = -6.37).

Bhat et al. [41] prepared some substituted pyrazoline derivatives 30 and evaluated for their in vitro cytotoxic activity against a panel of human cancer cell lines. Only eight compounds showed marked activity out of 93 screened compounds.

The antineoplastic activities a series of pyrazolinebearing benzimidazoles versus full NCI 60 cell panel have been reported by Shahrayar et al. [42] . Compound 31 demonstrated the best cytotoxic properties. It has high selectivity against certain cell lines including Leukemia CCRF-CEM and RPMI-8226 cell lines with GI 50 values of 2.23 and 2.76 µM, respectively [42] .

1-Acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives 32 and 33 have been reported by Manna et al. [43] , evaluated for their antineoplastic activity, and for their inhibitory effect on P-glycoprotein-mediated multidrug resistance protein (MDR1); which confers resistant to tumor cells by decreasing drug accumulation within tumor cells [44] . Both compounds 32 and 33 have been found to be active as MDR1 blockers. Johnson et al. synthesized the pyrazoline derivatives 34 in analogy to the natural cis-stilbine derivative combretastatin-A4 35, by replacement the ethylene-bridge with pyrazoline heterocycle, and tested for their anticancer activity [45] .

1,4-Diaryl-4,5-dihydropyrazoles 36 were reported by Roecker et al. to be mitotic kinesin spindle protein (KSP) inhibitors [46] with IC 50 value of 0.2 nM and cell EC 50 values of 3.2 nM. Some of the fused pyrazoline derivatives of cyclolignans 37 have been reported and evaluated for their cytotoxic activities in culture cells of P-388 murine leukemia, HT-29 colon carcinoma and A-549 lung carcinoma. Indene fused series of 3-(4-chlorophenyl)-[1,2-c]pyrazolines substituted with benzene sulfonamides, N1,N3-disubstituted sulfonylurea and sulfonylthiourea scaffolds 38,39 and some derived thiazolidinone and thiazoline ring systems have been synthesized by Rostom activity. Eight compounds showed promising broad-spectrum antitumor activity against most of the tested sub-panel tumor cell lines [47] .

Preparation of some pyrazole derivatives of related structure to the targeted pyrazolines 40 have been achieved by Coleman et al. [48] . The dihydropyrazole compounds of formula 40 are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin.

Breslin et al. [49] reported the preparation of 4,5-dihydro-1H-pyrazole derivatives 41 as potent mitotic kinesin inhibitors. The antineoplastic activities of compounds 41 have been evaluated by kinesin ATPase in vitro assay using human KSP motor domain, and it revealed potent binding affinity. Compound 42 was prepared from the starting precursor 43, and demonstrated IC 50 value £ 50 µM.

GLI proteins play pivotal roles in both cell proliferations and apoptosis [50] . It is also reported that blocking GLI genes is important in the initiation of DNA damage in early S-phase, leading to cell death in some human carcinomas [51] . He et al. [52, 53] reported the synthesis of dihydropyrazole carboxamides 44 that were used as kits for

Recent advances in the therapeutic applications of pyrazolines the diagnosis and treatment of cancers expressing a GLI polypeptide; in particular a GLI1, GLI2 or GLI3 polypeptide. All compounds were evaluated for their GLI polypeptide inhibitory activity. TGF-b is another cancer attractive target, since it is directly involved in apoptosis induction process [55] [56] [57] [58] . The preparation of fused dihydropyrazoles 46 as TGF-b signal transduction inhibitors have been synthesized by Sawyer et al. [59] . For instance, 1-{[2-(6-bromoquinolin-4-yl)-1-(pyridin-2-yl)ethylidene]amino}pyrrolidin-2-one was treated with sodium hydride (NaH) in dimethylformamide (DMF) at 80 --85 C for 18 h to afford the product 47 in 54% yield. The selected pyrazolines had IC 50 value below 20 µM for the TGF-b type I receptor.

The reported central nervous system (CNS) pharmacological actions of pyrazoline derivatives include antiepileptic and antidepressant effects; in addition to neurodegenerative disorders.

Ozdemir et al. [60] prepared 1-phenyl-1-thiocarbamoyland 1-N-substituted thiocarbamoyl-3-(2-furyl)-5-phenyl/ (2-furyl)-2-pyrazoline derivatives 48 --50 and studied their antiepileptic action by maximal electroshock seizure (MES) and subcutaneous pentylenetetrazole tests. Compounds 48 --50 were found to be protective against MES and subcutaneous metrazole (scMet) at 30 --300 mg/kg dose levels. Several 3-(3-acetoamino)phenyl-1,5-substituted phenyl-2-pyrazolines 51 --53 were synthesized by Singh et al. [61] and evaluated for their anticonvulsant activity. The synthesized pyrazolines 51 --53 exhibited anticonvulsant activity, which was reflected by 60 --80% protection observed versus PTZ-induced seizures. Those compounds exhibit their anticonvulsant potentials via inhibiting oxidation of certain nicotinamide--adenine--dinucleotide substrates.

A set of pyrazoline derivatives have been prepared by Shishikura et al. [62] and were used as kainic acid neurocytotoxicity inhibitors. The synthesized derivatives showed noncompetitive antagonism versus the non-N-methyl-D-aspartate (NMDA)-type ionotropic transmembrane receptor for glutamate AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors and are useful as nerve cell protectors, or in antiepileptic therapy. Particularly, the pyrazoline derivative; 1-benzoyl-4,5-dihydro-3,5-diphenyl-1H-pyrazole 54 and (+)-3-(1-benzoyl-5-phenyl-4,5-dihydro-1H-pyrazol-3-yl)pyridine 55 showed IC 50 of 2.6 and 1.3 µM versus AMPA receptors, respectively. Some quaternary ammonium salts of substituted pyrazoline compounds have been prepared by Torrens-Jover et al. [63] and evaluated for their use as medicaments for the treatment of humans and animals neurocytotoxicity. The pyrazoline derivative 1 was prepared by methylation of N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydropyrazole-3-carboxamide with methyl iodide. All of the synthesized pyrazolines were evaluated for their neurocytotoxicity inhibitory effect.

3,5-Diphenyl-2-pyrazoline derivatives 56 --58 showed decent antidepressant activities [64] . 3-(4-Methoxyphenyl)-5-(3,4-dimethoxyphenyl)-2-pyrazoline (56), 3-(4-methoxyphenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-2-pyrazoline (57) and 3-(4-chlorophenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-2-pyrazoline (58) reduced 41.9 --48.6% immobility times at 100 mg/kg dose level. From the structure--activity relationship (SAR) point of view, it was found that 4-methoxy and 4-chloro substituents on the phenyl ring at position-3 of the pyrazoline ring increased the antidepressant activity. Replacement of these groups by bromo and methyl substituents has negative impacts on the antidepressant properties.

Prasad et al. [65] synthesized some 1,3,5-triphenyl-2-pyrazolines having the general formula 59 

Recent advances in the therapeutic applications of pyrazolines 3-(2¢¢-hydroxynaphthalen-1¢¢-yl)-1,5-diphenyl-2-pyrazolines 60 and evaluated their antidepressant activity. The pyrazoline derivative 61 was found to reduce the immobility times by 25 --59% at 100 mg/kg dose level. It was found that compounds having electron-releasing groups on both aromatic rings at pyrazoline positions 3 and 5 dramatically enhanced the antidepressant activity when compared with the pyrazolines having no substituents on the aromatic rings [65] .

Similarly, some 1-phenyl-, 1-thiocarbamoyl-and 1-Nsubstituted thiocarbamoyl-3-(2-furyl)-5-phenyl/(2-furyl)-2-pyrazoline derivatives 62 and 63 were synthesized and investigated for their antidepressant activity by the Porsolt test (forced swimming test) in albino mice [66] .

Monoamine oxidase (MAO) inhibitors are wellestablished antidepressant agents [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] .

Gokhan-Kelekci et al. [78, 79] synthesized several pyrazoline derivatives such as 64a and evaluated their antidepressant potentials via measuring their MAO inhibitory activities. In addition, the anxiolytic and monoamine oxidase-A (MAO-A) and monoamine oxidase-B (MAO-B) inhibitory activities have been also evaluated by in vivo and/or in vitro tests. The synthesized compounds showed high activity against both MAO-A and MAO-B isoforms. Chimenti et al. [66] reported the synthesis of series of N1-propanoyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives 64b and tested their pharmacological activities as MAO inhibitors. Most of the tested compounds showed inhibitory activity within the micromolar range and high selectivity versus the more clinically important isozyme, that is, MAO-A [80] .

The antidepressant-like activities of compound X analogs were found to be favorably comparable with the clinically used fluoxetine [81] . This action was suggested to be mediated by modulating the CNS serotonin pathway [81] .

Jayaprakash et al. [82] synthesized a series of 3,5-diaryl carbothioamide pyrazoline derivatives 66 designed as mycobactin analogs (mycobacterial siderophore), and evaluated their antidepressant and MAO inhibitory activities. Interestingly, it was found that compound 67, which has antitubercular potential, acts also as a selective inhibitor of rat liver MAO-B. The substituted 1-thiocarbamoyl-3,5-diaryl-4,5-dihydro-(1H)-pyrazole derivatives 66 was found to selectively inhibit MAO-A and MAO-B isoforms [83] .

Manna et al. [43] synthesized a novel series of 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives and studied their ability to selectively inhibit MAOs, swine kidney oxidase and bovine serum amine oxidase. The pyrazoline 68 showed a potent MAO inhibitor with a Ki value of about 10 --8 nM.

A series of pyrazoles 69 were synthesized by Chimenti et al. [66, 84] and assayed as MAO inhibitors. Compound 69a showed inhibitory activity in micromolar range and high selectivity toward MAO-A isozyme. In addition, it was found to be useful as adjuvant therapy in the treatment of neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease.

The bis(3-aryl-4,5-dihydro-1H-pyrazole-1-carboxamide) derivatives 70 --71 were synthesized and screened for their anti-inflammatory properties utilizing in vivo acute carrageenan-induced paw edema standard method in rats [85] . This set of pyrazolines also demonstrated a decent inhibitory activity versus prostaglandin E2 (PGE2) that is responsible for fever [86] [87] [88] , at a dose level of 50 mg/kg [85] . The bis-pyrazoline derivative 70 exhibited considerable antiinflammatory properties [85] . Compounds 70 and 71 showed remarkable anti-inflammatory activities relative to indomethacin, as a standard reference, with a lower ulcer index values [85] .

Also, some novel bis(1-acyl-2-pyrazolines) derivatives 72 were synthesized by the same research group and screened for their anti-inflammatory and ulcerogenic activities as well. Some of the synthesized compounds showed advanced antiinflammatory properties with lower ulcerogenic liability than the standard used drug [89] .

A series of 3-(4-biphenyl)-5-substituted phenyl-2pyrazolines 73a and 1-benzoyl-3-(4-biphenyl)-5-substituted phenyl-2-pyrazolines 73b have been reported by Amir et al. and were screened for their anti-inflammatory and analgesic activities [90] .

2-Pyrazoline-bearing benzenesulfonamide derivatives 74 have been synthesized by Rathish et al. [91] and screened for their anti-inflammatory activity. Pyrazoline derivatives 74 were found to be more active than celecoxib throughout their study. Rani et al. [92] synthesized a series of pyrazoline derivatives pendent to an indole moiety and reported their evaluation for their anti-inflammatory activity against carrageenaninduced edema in albino rats at an oral dosage regimen of 50 mg/kg. All of the synthesized pyrazolines showed promising anti-inflammatory activity. 3-[1-Acetyl-5-(p-hydroxyphenyl)-2-pyrazolin-3-yl]indole (75) was found to be the most potent derivative in this series. It showed higher percentile of edema inhibition, along with lower ulcerogenic liability and acute toxicity than phenylbutazone as a standard drug [92] .

Compound 76 that bears an electron withdrawing nitro group in the aryl moiety showed good activity comparable with that of standard drugs pentazocin and diclofinac sodium [93] .

Rathish et al. synthesized a series of 1,3,5-trisubstituted pyrazolines-bearing benzene sulfonamides 77 and evaluated their anti-inflammatory activity. Among the tested compounds, several showed promising anti-inflammatory activity [91] . Some 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-indolylpyrazoline derivatives 78 were prepared and screened for cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitory activities [94] .

Phenyl-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole derivatives containing a thiocarbamoyl group such as 64 have been reported by Gokhan-Kelekci et al. [79] . The synthesized series of pyrazolines were tested for their in vivo antiinflammatory activity by two different bio-assays namely, carrageenan-induced edema and acetic acid-induced increase in capillary permeability in mice. Moreover, analgesic and ulcerogenic activities were also investigated.

A series of 5-(substituted) aryl-3-(3-coumarinyl)-1-phenyl-2-pyrazolines 79 have been synthesized by Khode et al. [95] and screened for in vivo anti-inflammatory and analgesic activities. Among the 12 prepared compounds, the pyrazoline derivatives 79 exhibited significant anti-inflammatory activity in a model of acute inflammation.

Shoman et al. [96] synthesized a group of NOdonating 2-pyrazoline derivatives 80 and evaluated for their anti-inflammatory activity using carrageenan-induced rat paw edema and compared with indomethacin as a known standard. The ability of the prepared derivatives to induce gastric toxicity was also evaluated. Most of the prepared series showed significant anti-inflammatory activity, with higher safety margins than indomethacin in regard to gastric toxicity. When NO-donating group was incorporated into the parent pyrazoline derivatives, they caused a non-significant reduction in the anti-inflammatory activity and a marked decrease in gastric ulcerations induced by pyrazolines that lack the same group.

Pyrazoline derivatives containing benzoxazole and benzimidazole moiety 81 have been reported by Kaplancikli et al. [97] . The synthesized compounds were evaluated for antinociceptive activities. Compounds 81 exhibited significant antinociceptive activities in both hot plate-and acetic acid-induced writhing tests. 

Recent advances in the therapeutic applications of pyrazolines

The pyrazolines 82 and 83 were synthesized by Godoy et al. [98] and tested for their antinociceptive activity [98] . Moreover, Godoy et al. has also investigated whether the pain relief effect is mediated by spinal noradrenergic or serotonergic systems. The results showed that, unlike the standard dipyrone, both spinal serotonin receptors and a2-adrenoceptors are involved in the antinociception induced by 82 and 83 [98] .

Pyrazoline ring represents a central scaffold for diverse antimicrobials that include antibacterials, antifungals, antivirals and antiamoebics. However, antitubercular could be considered a sub-class from antibacterials, we opted here to separate it under a specific subtitle, because of its clinical importance.

Several 1-(4-aryl-2-thiazolyl)-3-(2-thienyl)-5-aryl-2-pyrazoline derivatives 84 have been synthesized by Ozdemir et al. [99] and were evaluated for their antimicrobial activities against Escherichia coli, Bacillus cereus, Salmonella typhimurium, Streptococcus faecalis, Staphylococcus aureus, Aeromonas hydrophila, Candida glabrata and Candida albicans. A significant level of activity was observed.

In the same context, Abdel-Wahab et al. [100] reported the synthesis of several 3-(benzofuran-2-yl)-4,5-dihydro-5-aryl-1-[4-(aryl)-1,3-thiazol-2-yl]-1H-pyrazoles 85 and evaluated their antibacterial and antifungal activities. Some of the synthesized compounds showed enhanced antimicrobial activities than control drugs.

1,3-Diaryl-5-(cyano-, aminocarbonyl-and ethoxycarbonyl)-2-pyrazoline 86 and 1,3,4,5-tetra-aryl-2-pyrazoline derivatives 87 have been prepared by Abunada et al. [101] and screened for their antimicrobial activities against E. coli, S. aureus, Asperagillus flavus and C. albicans.

Bhatt et al. [102] synthesized several substituted pyrazolines 88 as potential antimicrobial agents. The synthesized 

Recent advances in the therapeutic applications of pyrazolines compounds were found to have remarkable activity against Bacillus megaterium Bacillus subtilis, E. coli and Mycobacterium tuberculosis H37Rv. The synthesis of pyrazoline derivatives of naproxen, as represented by compound 89, have been achieved by Udupi et al. [103] . The biological evaluation showed that some compounds of the series showed significant dual antimicrobial and anti-inflammatory activities.

Bharmal et al. [104] synthesized the pyrazoline derivative 90 with antimicrobial activity against Salmonella typhosa and Aspergillus niger.

Basawaraj et al. [105] reported the synthesis of some 1Hpyrazolines pendent to benzofuran 91a and 91b and tested their antimicrobial activity against both Gram-positive and Gram-negative bacteria represented by S. aureus and E. coli. Compounds 91a and 91b revealed potent antibacterial effect versus Gram-positive bacteria. By contrast, their antimicrobial effect has been significantly reduced in case of Gram-negative strains.

Some new pyrazolines and N-phenylpyrazolines, 92a and 92b have been prepared by Desai et al. [106] and evaluated for their antimicrobial activities. The synthesized compounds exhibited activity against Gram-positive bacteria.

Jamode et al. [107] reported the synthesis of the 1-isonicotinoyl/carboxamido-2-pyrazolines 93a and 93b and evaluated their antimicrobial properties against S. aureus, E. coli, Proteus mirabilis and Pseudomonas aeruginosa. Most of the pyrazoline derivatives were found to have moderate antibacterial activity.

A series of chlorofluoropyrazolines 94 were prepared by Karthikeyan et al. [108] . Some of such pyrazolines showed significant antibacterial and antifungal activity.

Treatment of the chalcones with nitromethane under Michael addition condition, followed by subsequent cyclization with thiosemicarbazide under basic reflux conditions gave 3-(benzofuran-2-yl)-5-(4-aryl)-4,5-dihydropyrazole-1-carbothioamides 95. These pyrazolines were further reacted with phenacyl bromides to afford thiazolesubstituted pyrazolines 96. Some of the compounds showed a significant antimicrobial activity against E. coli and A. niger [100] . Some N1-substituted 3,5-diphenylpyrazoline derivatives 97 have been synthesized by Chimenti et al. [83] and evaluated for their in vitro antibacterial activity against Helicobacter pylori.

Pyrasolines with an N1-acetyl group and 4-methoxy substituent in the 5-phenyl ring showed the highest activity against H. pylori metronidazole-resistant strains with minimum inhibitory concentration (MIC) value of 1 --4 µg/ml [83] .

Mogilaiah et al. [109] evaluated the antibacterial activities of the pyrazoline derivatives containing 1,8-naphthyridine moiety as represented by compound 98. The prepared compounds showed less activity than the standard aminogylcoside gentamycin. 

Recent advances in the therapeutic applications of pyrazolines Vijayvergiya et al. [110] synthesized some 3,5-diaryl-1-phenyl/isonicotinoyl-2-pyrazoline derivatives 99 and evaluated their antibacterial activity. The new pyrazolines showed remarkable antibacterial activity against Gram-positive bacteria S. aureus, Staphylococcus albus, Streptococcus pyogenes, Streptococcus viridans and Gram-negative bacteria E. coli and S. typhosa [110] .

Waheed and Khan [111] synthesized some derived substituted 1,2-pyrazolines 100 from nalidixic acid as antibacterial and analgesic agents. These pyrazolines were found to have a significant antibacterial activity against Gram-negative bacteria and possessed appreciable analgesic activity.

Stirrett et al. [112] synthesized some pyrazolines represented by compound 101 with structural similarities to siderophores and evaluated their ability as novel antimicrobials against M. tuberculosis and Yersinia pestis.

1,3,5-Trisubstituted-2-pyrazolines 102 were reported by Shenoy et al. [113] and were tested for their antimicrobial activity. Some of the compounds exhibited potential antitubercular activity.

Zampieri et al. [118] reported the synthesis of 1-(3,5-diaryl-4,5-dihydro-1H-pyrazol-4-yl)-1H-imidazole derivatives 103 and tested them against strains of C. albicans and a strain of M. tuberculosis H37Rv.

Shaharyar et al. presented a series of N1-nicotinoyl-3-(4-hydroxy-3-methylphenyl)-5-(substituted phenyl)-2-pyrazolines 104 and tested them in vitro for their antimycobacterial activity. Some of these pyrazolines were found to be an active agent against different strains of TB, with MIC value of 0.26 µM [114] . 5-Aryl-1-isonicotinoyl-3-(pyridin-2-yl)-4,5-dihydro-1Hpyrazole derivatives 105 have been synthesized by Mamolo et al. [115] and tested for their in vitro antimycobacterial activity. The latter pyrazoline derivative showed an interesting activity against different strains of M. tuberculosis.

Several 1-[(N,N-disubstituted thiocarbamoylthio)acetyl]-3-(2-thienyl)-5-aryl-2-pyrazoline derivatives 106 were synthesizes by Ozdemir et al. [116] and Shaharyar et al. [114] and evaluated for their in vitro antimycobacterial activity against H37Rv strain.

The potential benefits of medicaments endowed with both antimycobacterial and antifungal characters represent a valuable goal, since the association between TB and mycotic infections often occurs in immunocompromised patients [117] . So far, some 1,3,5-triryl-4,5-dihydro-1H-pyrazoles, as represented by structure 107, pendent to 1H-imidazole ring have been reported by Zampieri et al. [118] and tested for their in vitro antifungal and antimycobacterial activities. These imidazole-substituted pyrazole derivatives showed significant antifungal activity against a clinical strain of C. albicans and remarkable antitubercular activity against M. tuberculosis H37Rv.

A series of heterocyclic-substituted diphenyl ether derivatives of pyrazoles 108 have been synthesized and evaluated for their activity against H37Rv strain of Mycobacterium. Ten compounds inhibited the growth at concentrations as low as 1 µg/ml. This level of activity was found comparable with the reference drugs rifampicin and isoniazid at the same concentration [119] .

Another series of 5-(4-(substituted)phenyl)-3-(4-hydroxy-3-methylphenyl)-4,5-dihydro-1H-1-pyrazolyl-2-toluidinomethanethione and 5-(substituted)phenyl-3-(4-hydroxy-3methylphenyl)-4,5-dihydro-1H-1-pyrazolyl-2-methoxyanilino methanethione derivatives were synthesized by Ali et al. [120] and tested for their in vitro antitubercular activity against M. tuberculosis H37Rv. Compound 109 was found to be the most active with MIC value of 0.0034 µM [120] .

Babu et al. [121] evaluated the biological activity of 1,3,5-trisubstituted pyrazolines-bearing benzofuran moiety 110a and 110b. These compounds have been found to have some antitubercular effect. [122] . The results showed that these compounds exhibited promising antiamoebic activity (IC 50 = 0.05, 0.31, 0.06 and 0.29 µM, respectively) [122] . A variety of 3-(3-bromophenyl)-5-phenyl-1-(thiazolo[4,5-b] quinoxaline-2-yl)-2-pyrazoline derivative, as represented by compound 112, have been achieved by Budakoti et al. [123] , and screened for their antiamoebic activity against HMI: IMSS strain of E. histolytica by micro-dilution method which compared the IC 50 values with the standard drug metronidazole [123] . Also, the same authors have synthesized a novel Pd (II) complexes with 1-N-substituted thiocarbamoyl-3,5-diphenyl-2-pyrazoline (Budakoti et al. [124] ) and evaluated their antiamoebic activity by micro-dilution method against HM1:IMSS strain of E. histolytica and compared the results with the standard drug metronidazole. These palladium complexes showed better activity than their corresponding ligands. The pyrazoline 113a showed better inhibitory [124] . Similarly, Husain et al. reported another series of Pd(II) complexes, represented below by the most active compound 113b [125] . But this series of compounds were less active than 113a in terms of IC 50 values; however, complex 113b (IC 50 = 0.37 µM) is more active than metronidazole [125] .

Abid et al. [126, 127] synthesized a series of 1-N-substituted thiocarbamoyl-3-phenyl-2-pyrazoline derivatives 114 by cyclization of Mannich bases with thiosemicarbazide and evaluated their in vitro antiamoebic activities against E. histolytica in comparison with metronidazole as reference drug. The preliminary SARs indicated that the substitution of 3-chloro or 3-bromo on the phenyl ring at pyrazoline position-3 markedly enhanced the antiamoebic activity. Moreover, compound 115 showed the most promising antiamoebic activity with an IC 50 value of 0.6 versus 1.8 µM of metronidazole.

Another new series of pyrazoline derivatives were synthesized by cyclization of Mannich bases with thiosemicarbazides being substituted by different cyclic and aromatic amines and screened for in vitro antiamoebic activity against E. histolytica. The pyrazoline 116 was found to be the most active compound in this series [126] . The Pd(II) complexes of these derivatives have been also prepared and evaluated for their antiamoebic activity [128] . As observed previously, the Pd(II) complexes exhibited stronger antiamoebic activity [128] . Bhat et al. reported some interesting bis-pyrazolines 117 prepared by cyclization of chalcones with N-4-substituted thiosemicarbazides under basic conditions. Investigation of the antiamoebic activity showed that compounds with aromatic substituents at the thiocarbamoyl group were more active than those with the cyclic groups [129] .

Semicarbazone-based pyrazoline derivatives, represented by compound 118, have been designed as drug candidates for Chagas' disease (American trypanosomiasis) [130] . Compound 118 showed inhibitory activity versus Trypanosoma cruzi as low as 80 nM. Compound 118 and its analogs exhibited their antitrypanosomal activities by targeting cysteine protease cruzain, interestingly, with low cellular toxicity [130] . 

Some new N-acetyl and N-thiocarbamoyl derivatives of 4,5-dihydropyrazoles were synthesized by El-Sabbagh et al. and were tested against a broad panel of viruses in different cell cultures [132] . N-Acetyl-4,5-dihydropyrazole was the only active compound at sub-toxic concentrations against vaccinia virus (Lederle strain) in HEL cell cultures with an EC 50 value of 7 µg/ml [132] .

Yar et al. reported the synthesis of new pyrazolines derived from phenoxyacetic acid. The synthesized derivatives were tested for their in vitro cytotoxicity and antiviral activity. In addition to the antiviral activity of 2-{4-[3-(2,4-dihydroxyphenyl)-1-(2-hydroxybenzoyl-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetic acid (120) , it showed the maximum cytotoxicity of the series [133] [134] [135] .

A series of trisubstituted pyrazolines 121a and 121b showed an inhibition for flavivirus infection in cell culture and was identified through high-throughput screening of a compound library using a luciferase-expressing West Nile virus (WNV) infection assay [136] . The aryl-rings in such pyrazolines are essential for the activity against WNV. The pyrazolines inhibitors of RNA synthesis that were investigated pointed the viral RNA polymerase, RNA helicase or other viral replication enzymes as potential targets [137] .

Liang et al. [138] reported the synthesis of the 3,5-diaryl-4,5-dihydropyrazole derivatives 122, which inhibits the activity of picornavirus and coronavirus simultaneously. These compounds could be used for preventing and treating diseases caused by pecorino virus and coronavirus, such as influenza, foot-and-mouth disease, epidemic keratoconjunctivitis, aseptic meningitis, myocarditis, hepatitis A and severe acute respiratory syndrome (SARS).

Silver and Soderlund [139] synthesized some insecticides that are related to the pyrazolines 123a and 123b and examined their mechanism of action based on electrophysiological, pharmacological and toxicological information. Eventually, it was found that these compounds exert their insecticidal activity via neuronal targets [139] .

Turan-Zitouni et al. [140] synthesized several 1-(4-arylthiazol-2-yl)-3,5-diaryl-2-pyrazolines 124 and studied their hypotensive activity by the tail-cuff method. All the synthesized pyrazolines showed appreciable hypotensive activities comparable with clonidine as a reference drug.

A series of 3-(3,5-dialkyl-4-hydroxyphenyl)-5-(multi-substituted-4-hydroxyphenyl)-2-pyrazolines were prepared and evaluated their inhibitory action on acyl-coenzyme A cholesterol acyltransferase (ACAT), which is responsible for formation of cholesterol precursor acetoacetyl CoA in the mevalonate pathway [141] . The pyrazoline 125 as an example of this series showed in vitro inhibitory activity on hACAT-1 and -2 [142] .

Substituted pyrazoline derivatives of the general formula 126 with ACAT inhibition activity were prepared and their pharmaceutical compositions and uses in the treatment of dyslipidemia have been reported by Yenes-Minguez and Torrens-Jover [134, 143] . 

A novel series of pyrazoline derivatives have been synthesized by Babu et al. [146] and evaluated for their antioxidant activity at various concentrations against standard ascorbic acid. The pyrazoline 132 among the series of the synthesized compounds showed excellent antioxidant activity as compared with ascorbic acid.

Zhang et al. designed several pyrazolines of the general formula 133 and evaluated them by in vivo screening as tissue selective androgen receptor modulators (SARMs). SARs were investigated at the R 1 to R 6 positions as well as the core pyrazoline ring and the anilide linker. It was found that, strong electron-withdrawing groups at the R 1 and R 2 positions and small groups at the R 5 and R 6 positions were optimal for androgen receptor agonist activity [147] . Jones et al. achieved the synthesis of 4-substituted pyrazoline derivatives 134 and studied their docking into a protein receptor homology model. The results of the study revealed that the synthesized compounds exhibited functional antagonism of protein receptor [148] .

A series of interesting androstano[17,16-c]pyrazolines and their oxidized derivatives 135 have been synthesized and evaluated for their anti-androgenic activity compared with that of cyproterone as a positive control. Some of these compounds showed better anti-androgenic activity than the reference drug [149] .

Fisas-Escasany et al. [150, 151] achieved preparation of substituted pyrazolines 136 in order to be used in combination therapy with other antidiabetic agents.

The human urotensin II receptor (h-UTR) is a member of the family of rhodopsin-like G-protein-coupled receptors (GPCRs) involved in the modulation of the functionality of many tissues and organs. A combinatorial scaffold approach has been reported by Olsson [152] to build a library of compounds having four diversity points. The synthesized compounds provide the mapping of urotensin II and somatostatin-5 receptors by differential binding of the receptors.

From the aforementioned examples, pyrazoline heterocyclic ring was mainly used as a structural core for building huge variety of biologically active compounds. The versatile pyrazoline structure with semi-saturated status provides a unique spatial configuration which allows various substitution patterns. Figure 3 shows eight possible patterns of only two substitutions. One can imagine the diversity in cases of three or more substituents.

Among the reported activities, there are some important notes; pyrazoline-containing cytotoxic compounds are not only useful in treatment of various cancer types, but also some of them act as cancer chemopreventive agents. Concerning the reported antimycobaterium activity of pyrazoline-containing compounds, all reports have been assayed utilizing the vaccine-strain H37Rv and not the infectious strains, which make the biological impacts doubtful. Evaluating those compounds versus multidrugresistant (MR-TB) or extreme drug-resistant (XDR-TB) mycobacterium strains will add huge value to the present work.

The reported articles are hampered by lacking molecular target identification. Most of the reported biological activities for pyrazoline-containing compounds were based on cellbased assays, and the authors have not reported anything about the possible molecular target. So far, these kinds of drug development protocols do not allow conducting structure-based drug design approaches. From our point of view, more attention has to be given for the molecular basis of mode of actions. Hence, rational drug design methods could be applied and more drug-like candidates will likely be obtained.

The authors state no conflict of interest and have received no payment in preparation of this manuscript.

Papers of special note have been highlighted as either of interest () or of considerable interest () to readers. 28. Vela Hernandez JM, Yenes-Minguez S. Preparation of (4S,5S)-5-(4chlorophenyl)-1-(2,4-dichlorophenyl)-N-(cis-2,6-dimethylpiperidin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide as a cannabinoid CB1 neutral antagonist for treatment of food intake disorders. PCT Int Appl. WO2009124950A220091015; 2009 29. Vela Hernandez JM, Yenes-Minguez S. Preparation of (4S,5S)-5-(4chlorophenyl)-1-(2,4-dichlorophenyl)-N-(cis-2,6-dimethylpiperidin-1-yl)-4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide as a cannabinoid CB1 neutral antagonist for treatment of food intake disorders. A combinatorial scaffold approach has been reported to build a library of compounds having four diversity points. The synthesized compounds provide the mapping of urotensin II and somatostatin-5 receptors by differential binding of the receptors.

Pyrazoline bearing benzimidazoles: search for anticancer agent

Inhibition of amine oxidases activity by 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives

Reversal of drug-sensitivity in multidrug-resistant tumor-cells by an MDR1 (Pgy1) Ribozyme

Design, synthesis, and biological testing of pyrazoline derivatives of combretastatin-A4

Kinesin spindle protein (KSP) inhibitors. Part 8: design and synthesis of 1,4-diaryl-4,5-dihydropyrazoles as potent inhibitors of the mitotic kinesin KSP

Synthesis and in vitro antitumor evaluation of some indeno [1,2-c]-pyrazol(in)es substituted with sulfonamide, sulfonylurea(-thiourea) pharmacophores, and some derived thiazole ring systems

Preparation of pyrazole derivatives as mitotic kinesin inhibitors

4,5-Dihydro-1H-pyrazole derivatives useful as mitotic kinesin inhibitors, and their pharmaceutical compositions and use in the treatment of cancer

Cooperative E-box regulation of human GLI1 by TWIST and USF

Blocking hedgehog survival signaling at the level of the GLI genes induces DNA damage and extensive cell death in human colon carcinoma cells

TGF-beta 1 induces caspase-dependent but death-receptor independent apoptosis in lymphoid cells

Preparation of substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles as TGF-beta signal transduction inhibitors

Synthesis and studies on antidepressant and anticonvulsant activities of some 3-(2-furyl)-pyrazoline derivatives

Anticonvulsant activity and selective-inhibition of nicotinamide adenine dinucleotide-dependent oxidations by 1,3,5-Trisubstituted Pyrazolines

Preparation of acylazole derivatives as kainic acid neurocytotoxicity inhibitors

Quaternary ammonium salts of substituted pyrazoline compounds, their preparation and use as medicaments

Synthesis and antidepressant activities of some 3,5-diphenyl-2-pyrazolines

Synthesis and antidepressant activity of some 1,3,5-triphenyl-2-pyrazolines and 3-(2''-hydroxynaphthalen-1''-yl)-1,5-diphenyl-2-pyrazolines

Synthesis, molecular modeling studies and selective inhibitory activity against MAO of N1-propanoyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives

Atypical depression: is there still evidence for superiority of MAO-inhibitors'?

Drug therapies for depression: from MAO inhibitors to substance P

The role of MAO inhibitors on the treatment of depression

Efficacy of reversible inhibitors of MAO-A (Rima) in various forms of depression

The concept of atypical depression and its relation to successful treatments with MAO-Inhibitors

Treatment strategy in depression. 2. MAO inhibitors in depression resistant to cyclic antidepressants -2 controlled crossover studies with tranylcypromine versus L-5-Hydroxytryptophan and Nomifensine

MAO-inhibitors and sleep in major depression

The efficacy of MAO inhibitors in depression --a metaanalysis

MAO inhibitors in chronic pain and depression

Combination of tricyclic anti-depressants and MAO inhibitors in treatment of depression

New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity

A new therapeutic approach in Alzheimer disease: some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics

A clinical-study of the selective MAO-A inhibitor Moclobemide (RO11-1163) --a comparison of 2 different dosages with particular reference to platelet Mao-activity and urinary Mhpg-excretion

New pyrazoline derivatives and their antidepressant activity

Pyrazoline-based mycobactin analogues as MAO-inhibitors

Synthesis and in vitro selective anti-Helicobacter pylori activity of pyrazoline derivatives

Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1H)-pyrazole derivatives

Facile synthesis of bis(4,5-dihydro-1H-pyrazole-1-carboxamides) and their thio-analogues of potential PGE(2) inhibitory properties

Prostaglandin-E2 as a central messenger of fever -mechanism of formation

Prostaglandin-E2 in the pathogenesis of Pyrogen fever -validation of an intermediary role

Pyrogenic immunomodulators increase the level of prostaglandin-E2 in the blood simultaneously with the onset of fever

Novel bis(1-acyl-2-pyrazolines) of potential anti-inflammatory and molluscicidal properties

Synthesis and pharmacological evaluation of pyrazoline derivatives as new anti-inflammatory and analgesic agents

Synthesis and antiinflammatory activity of some new 1,3,5-trisubstituted pyrazolines bearing benzene sulfonamide

Synthesis and antiinflammatory activity of heterocyclic indole derivatives

Synthesis and pharmacological study of 1-acetyl/propyl-3-aryl-5-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)-2-pyrazoline

Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl) 3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitor

This paper describes the integrated effect in trifluoromethylpyrazoline derivatives and their evaluation for COX-2 and LOX inhibitory activities

Synthesis and pharmacological evaluation of a novel series of 5-(substituted) aryl-3-(3-coumarinyl)-1-phenyl-2-pyrazolines as novel anti-inflammatory and analgesic agents

Synthesis and investigation of anti-inflammatory activity and gastric ulcerogenicity of novel nitric oxide-donating pyrazoline derivatives

Synthesis and antinociceptive activities of some pyrazoline derivatives

alpha(2)-adrenoceptors and 5-HT receptors mediate the antinociceptive effect of new pyrazolines, but not of dipyrone

Synthesis and antimicrobial activity of 1-(4-aryl-2-thiazolyl)-3-(2-thienyl)-5-aryl-2-pyrazoline derivatives

Synthesis and antimicrobial evaluation of 1-(benzofuran-2-yl)-4-nitro-3-arylbutan-1-ones and 3-(benzofuran-2-yl)-4,5-dihydro-5-aryl-1-[4-(aryl)-1,3-thiazol-2-yl]-1H-pyrazoles

Synthesis and biological activity of some new pyrazoline and pyrrolo[3,4-c]pyrazole-4,6-dione derivatives: Reaction of nitrilimines with some dipolarophiles

Synthesis of pyrazolines and cyanopyridines as potential antimicrobial agents

Synthesis and biological evaluation of certain pyrazoline derivatives of 2-[6-methoxy naphthyl]-propionic acid (Naproxen)

Synthesis of some pyrazoline derivatives as biologically active agents

Synthesis of some 1H-pyrazolines bearing benzofuran as biologically active agents

Synthesis and antimicrobial activities of some new pyrazolines phenyl pyrazolines, flavanones and related compounds

Synthesis and antimicrobial evaluation of some 1-isonicotinoyl/carboxamido-2-pyrazolines

Synthesis and antimicrobial studies on novel chloro-fluorine containing hydroxy pyrazolines

Synthesis and antibacterial activities of 1,3,4-oxadiazole and pyrazoline derivatives containing 1,8-naphthyridine moiety

Synthesis and biological activity of some new 3,5-diaryl-1-phenyl/isonicotinoyl-2-pyrazolines and 3,5-diaryl-6-carbethoxy cyclohexenone derivatives

Synthesis of certain substituted 1,2 pyrazolines from nalidixic acid as antibacterial and analgesic agents

Small molecules with structural similarities to siderophores as novel antimicrobials against Mycobacterium tuberculosis and Yersinia pestis

Synthesis and antimicrobial activities of 1,3,5 trisubstituted 2-pyrazolines

) nicotinoyl-3-(4'-hydroxy-3'-methylphenyl)-5-[(sub)phenyl]-2-pyrazolines

Synthesis and antimycobacterial activity of 5-aryl-1-isonicotinoyl-3-(pyridin-2-yl)-4,5-dihydro-1H-pyrazole derivatives

Novel analogues of 2-Pyrazoline: synthesis, characterization, and antimycobacterial evaluation

Azole-antifungal binding to a novel cytochrome P450 from Mycobacterium tuberculosis: implications for treatment of tuberculosis

Antifungal and antimycobacterial activity of 1-(3,5-diaryl-4,5dihydro-1H-pyrazol-4-yl)-1H-imidazole derivatives

Synthesis, antitubercular activity and docking study of novel cyclic azole substituted diphenyl ether derivatives

Synthesis, structural activity relationship and anti-tubercular activity of novel pyrazoline derivatives

Synthesis and biological evaluation of 1,3,5-trisubstituted pyrazolines bearing benzofuran

Synthesis, characterization, antiamoebic activity and cytotoxicity of novel series of pyrazoline derivatives bearing quinoline tail

Syntheses and evaluation of 3-(3-bromo phenyl)-5-phenyl-1-(thiazolo[4,5-b] quinoxaline-2-yl)-2-pyrazoline derivatives

Syntheses, characterization and in vitro antiamoebic activity of new Pd(II) complexes with 1-N-substituted thiocarbamoyl-3,5-diphenyl-2-pyrazoline derivatives

Novel Pd (II) complexes of 1-N-substituted 3-phenyl-2-pyrazoline derivatives and evaluation of antiamoebic activity

Synthesis, spectral studies and antiamoebic activity of new 1-N-substituted thiocarbamoyl-3-phenyl-2-pyrazolines

Synthesis and antiamoebic activities of 1-N-substituted cyclised pyrazoline analogues of thiosemicarbazones

Synthesis and antiamoebic activity of new 1-N-substituted thiocarbamoyl-3,5-diphenyl-2-pyrazoline derivatives and their Pd(II) complexes

Bispyrazolines: synthesis, characterization and antiamoebic activity as inhibitors of growth of Entamoeba histolytica

Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain

Synthesis and antiviral activity of new pyrazole and thiazole derivatives

Substituted pyrazoline compounds with ACAT inhibition activity, their preparation and use as medicaments in the treatment of dyslipidemia

Substituted pyrazoline compounds with ACAT inhibition activity and their preparation, pharmaceutical compositions and use in treatment of dyslipidemia

Synthesis and evaluation of in vitro antiviral activity of novel phenoxy acetic acid derivatives

Triaryl pyrazoline compound inhibits flavivirus RNA replication

Identification of compounds with anti-West Nile Virus activity

Pyrazole derivatives for preventing and treating diseases caused by picornavirus and coronavirus. Repub Korean Kongkae Taeho Kongbo

Action of pyrazoline-type insecticides at neuronal target sites

Synthesis of some thiazolyl-pyrazoline derivatives and preliminary investigation of their hypotensive activity

Regulation of acyl-coenzyme A: cholesterol acyltransferase (ACAT) synthesis, degradation, and translocation by high-density lipoprotein(2) at a low concentration

Novel 3,5-diaryl pyrazolines as human acyl-CoA: cholesterol acyltransferase inhibitors

Substituted pyrazoline compounds with ACAT inhibition activity and their preparation, pharmaceutical compositions and use in treatment of dyslipidemia